Naoko Suenaga

1.2k total citations
17 papers, 981 citations indexed

About

Naoko Suenaga is a scholar working on Cancer Research, Molecular Biology and Oncology. According to data from OpenAlex, Naoko Suenaga has authored 17 papers receiving a total of 981 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Cancer Research, 5 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Naoko Suenaga's work include Protease and Inhibitor Mechanisms (5 papers), Cell Adhesion Molecules Research (4 papers) and Infectious Encephalopathies and Encephalitis (3 papers). Naoko Suenaga is often cited by papers focused on Protease and Inhibitor Mechanisms (5 papers), Cell Adhesion Molecules Research (4 papers) and Infectious Encephalopathies and Encephalitis (3 papers). Naoko Suenaga collaborates with scholars based in Japan, United States and United Kingdom. Naoko Suenaga's co-authors include Motoharu Seiki, Susumu Furukawa, Takashi Ichiyama, Masahiro Kajita, Hidetoshi Mori, Danmei Xu, Ruth J. Muschel, Mariola J. Edelmann, Katsuyuki Fujii and Junko Ueda and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Oncogene.

In The Last Decade

Naoko Suenaga

17 papers receiving 963 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Naoko Suenaga Japan 13 394 299 285 170 133 17 981
Lucia De Monte Italy 22 632 1.6× 823 2.8× 141 0.5× 99 0.6× 145 1.1× 50 2.1k
Christine Schweitzer Germany 14 276 0.7× 254 0.8× 120 0.4× 87 0.5× 51 0.4× 18 924
Marianne Strazza United States 18 397 1.0× 387 1.3× 156 0.5× 65 0.4× 84 0.6× 39 1.3k
Sivan Cohen Israel 20 677 1.7× 353 1.2× 317 1.1× 99 0.6× 33 0.2× 36 1.9k
Helmut Deißler Germany 20 484 1.2× 282 0.9× 112 0.4× 92 0.5× 132 1.0× 40 937
Evelyne Zeira Israel 17 429 1.1× 512 1.7× 149 0.5× 58 0.3× 51 0.4× 21 1.3k
Mark Allegretta United States 20 492 1.2× 344 1.2× 135 0.5× 86 0.5× 53 0.4× 32 1.9k
Emy J. Chen United States 7 857 2.2× 302 1.0× 288 1.0× 87 0.5× 64 0.5× 7 1.4k
Karl X. Chai United States 24 796 2.0× 270 0.9× 278 1.0× 125 0.7× 160 1.2× 48 1.6k
Takeharu Sakamoto Japan 22 587 1.5× 307 1.0× 566 2.0× 108 0.6× 127 1.0× 54 1.2k

Countries citing papers authored by Naoko Suenaga

Since Specialization
Citations

This map shows the geographic impact of Naoko Suenaga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naoko Suenaga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naoko Suenaga more than expected).

Fields of papers citing papers by Naoko Suenaga

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naoko Suenaga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naoko Suenaga. The network helps show where Naoko Suenaga may publish in the future.

Co-authorship network of co-authors of Naoko Suenaga

This figure shows the co-authorship network connecting the top 25 collaborators of Naoko Suenaga. A scholar is included among the top collaborators of Naoko Suenaga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naoko Suenaga. Naoko Suenaga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Ribrag, Vincent, Zev A. Wainberg, Lara Iglesias Docampo, et al.. (2022). Pharmacokinetic and pharmacodynamic activity evaluation of MAK683, a selective oral embryonic ectoderm development (EED) inhibitor, in adults with advanced malignancies in a first-in-human study.. Journal of Clinical Oncology. 40(16_suppl). 3083–3083. 2 indexed citations
2.
Ando, Yuichi, Satoru Iwasa, Shunji Takahashi, et al.. (2018). Phase I study of alpelisib (BYL719), an α‐specific PI3K inhibitor, in Japanese patients with advanced solid tumors. Cancer Science. 110(3). 1021–1031. 41 indexed citations
3.
Nishio, Makoto, Haruyasu Murakami, Atsushi Horiike, et al.. (2015). Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non–Small-Cell Lung Cancer or Other Tumors. Journal of Thoracic Oncology. 10(7). 1058–1066. 58 indexed citations
4.
Murakami, Haruyasu, Takashi Seto, Toshiaki Takahashi, et al.. (2014). Phase I Study for Ceritinib (Ldk378) in Japanese Patients with Alk Genetic Alterations. Annals of Oncology. 25. iv456–iv456. 1 indexed citations
5.
Ando, Yukio, Ayako Mitsuma, Takayuki Yoshino, et al.. (2014). Phase I dose‐escalation study of buparlisib (BKM120), an oral pan‐class I PI3K inhibitor, in Japanese patients with advanced solid tumors. Cancer Science. 105(3). 347–353. 73 indexed citations
6.
Xu, Danmei, Naoko Suenaga, Mariola J. Edelmann, et al.. (2008). Novel MMP-9 Substrates in Cancer Cells Revealed by a Label-free Quantitative Proteomics Approach. Molecular & Cellular Proteomics. 7(11). 2215–2228. 139 indexed citations
7.
Ichiyama, Takashi, Naoko Suenaga, Madoka Kajimoto, et al.. (2007). Serum and CSF levels of cytokines in acute encephalopathy following prolonged febrile seizures. Brain and Development. 30(1). 47–52. 87 indexed citations
8.
Kajimoto, Madoka, et al.. (2007). West syndrome associated with mosaic Down syndrome. Brain and Development. 29(7). 447–449. 4 indexed citations
9.
Suenaga, Naoko, Takashi Ichiyama, Masaya Kubota, et al.. (2007). Roles of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 in acute encephalopathy following prolonged febrile seizures. Journal of the Neurological Sciences. 266(1-2). 126–130. 64 indexed citations
10.
Ichiyama, Takashi, Tsuneo Morishima, Naoko Suenaga, et al.. (2005). Analysis of serum soluble CD40 ligand in patients with influenza virus-associated encephalopathy. Journal of the Neurological Sciences. 239(1). 53–57. 10 indexed citations
11.
Ichiyama, Takashi, et al.. (2005). Analysis of cytokine levels in cerebrospinal fluid in mumps meningitis: Comparison with echovirus type 30 meningitis. Cytokine. 30(5). 243–247. 24 indexed citations
12.
Ichiyama, Takashi, et al.. (2005). Serum levels of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) in acute disseminated encephalomyelitis. Journal of Neuroimmunology. 172(1-2). 182–186. 31 indexed citations
13.
Ichiyama, Takashi, et al.. (2005). [Low-dose therapy with carbamazepine for convulsions associated with mild gastroenteritis].. PubMed. 37(6). 493–7. 14 indexed citations
14.
Suenaga, Naoko, Hidetoshi Mori, Yoshifumi Itoh, & Motoharu Seiki. (2004). CD44 binding through the hemopexin-like domain is critical for its shedding by membrane-type 1 matrix metalloproteinase. Oncogene. 24(5). 859–868. 91 indexed citations
15.
Nakamura, Hiroyuki, Naoko Suenaga, Hirokazu Matsuki, et al.. (2004). Constitutive and Induced CD44 Shedding by ADAM-Like Proteases and Membrane-Type 1 Matrix Metalloproteinase. Cancer Research. 64(3). 876–882. 115 indexed citations
16.
Funato, Yosuke, Takeshi Terabayashi, Naoko Suenaga, et al.. (2004). IRSp53/Eps8 Complex Is Important for Positive Regulation of Rac and Cancer Cell Motility/Invasiveness. Cancer Research. 64(15). 5237–5244. 111 indexed citations
17.
Ueda, Junko, Masahiro Kajita, Naoko Suenaga, Katsuyuki Fujii, & Motoharu Seiki. (2003). Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: importance of MT1-MMP as a therapeutic target for invasive tumors. Oncogene. 22(54). 8716–8722. 116 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lucia De Monte Breakdown of academic impact, for papers by Christine Schweitzer Breakdown of academic impact, for papers by Marianne Strazza Breakdown of academic impact, for papers by Sivan Cohen Breakdown of academic impact, for papers by Helmut Deißler Breakdown of academic impact, for papers by Evelyne Zeira Breakdown of academic impact, for papers by Mark Allegretta Breakdown of academic impact, for papers by Emy J. Chen Breakdown of academic impact, for papers by Karl X. Chai Breakdown of academic impact, for papers by Takeharu Sakamoto
Rankless by CCL
2026